Glaucoma News

Immunovant Stock Plummets After Thyroid Eye Disease Trial Setback The world of biotech investing is not for the faint of heart, a truth hammered home yet again as shares of Immunovant, Inc. (NASDAQ: IMVT) went into a tailspin. The catalyst? A significant and unexpected setback in a crucial late-stage clinical trial, sending shockwaves through the […]

Understanding Astigmatism: A Common Eye Condition Affecting Millions Have you ever experienced blurred or distorted vision at all distances, even with your glasses on? Do lights at night appear with annoying streaks or halos? If so, you might be one of the millions of people worldwide living with astigmatism. Far from being a disease or

Immunovant’s Batoclimab Fails Phase 3 Trial for Thyroid Eye Disease The landscape for treating Thyroid Eye Disease (TED), a painful and vision-threatening autoimmune condition, has seen significant innovation in recent years. However, the path forward is not without its setbacks. In a significant development, Immunovant Inc. has announced that its lead investigational drug, batoclimab, did

Protect Your Vision: Essential Eye Health Tips for Prevention of Blindness Week Every year, Prevention of Blindness Week serves as a crucial reminder of a startling fact: up to 80% of all vision impairment is avoidable. From simple lifestyle adjustments to proactive medical care, the power to protect our sight lies largely in our own

Immunovant’s Eye Disease Drug Fails Pivotal Phase 3 Trial In a significant setback for patients and the biotech company, Immunovant has announced that its investigational drug for thyroid eye disease (TED) failed to meet its primary endpoint in a crucial Phase 3 clinical trial. The news, released on April 2, 2026, sent shockwaves through the

Sight Sciences to Showcase Glaucoma and Dry Eye Innovations at ASCRS 2026 The landscape of ophthalmic care is poised for a significant update as Sight Sciences, Inc. prepares to take center stage at the upcoming 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting. The company has announced that its portfolio of interventional

AI Eye Exams Predict Heart Disease Risk in Routine Checkups For decades, the routine eye exam has been a window to the soul of our vision health. But what if that same quick, non-invasive look could also reveal the secrets of your heart? Groundbreaking new research suggests that artificial intelligence (AI), trained to analyze scans

Viridian Stock Crashes 34% After Eye Drug Efficacy Disappoints The brutal reality of biotech investing was on full display this week as Viridian Therapeutics saw its stock price plunge by a staggering 34% in a single day. The catalyst? Clinical trial results for its promising eye disease drug, VRDN-001, which delivered a paradoxical blow: it

Viridian’s Thyroid Eye Disease Drug Stumbles, Stock Plummets 30% The race to challenge Amgen’s blockbuster thyroid eye disease (TED) drug, Tepezza, just hit a major roadblock. Viridian Therapeutics, a biotech firm that had been gaining significant attention from investors, saw its stock price crater by over 30% following the release of disappointing early-stage clinical trial